ACRS: Aclaris Therapeutics, Inc.
About
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.
Current Value
$4.441 Year Return
Current Value
$4.441 Year Return
Key Details
Market Cap
$327.87M
P/E Ratio
-8.83
1Y Stock Return
415.67%
1Y Revenue Growth
26.35%
Dividend Yield
0.00%
Price to Book
2.5
Strategies that include ACRS
Stock's related to ACRS
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| DMRC | 37.08% | $694.39M | -2.06% | 0.00% |
| MDGL | 28.25% | $6.85B | +66.72% | 0.00% |
| SYRE | 27.03% | $1.38B | +169.81% | 0.00% |
| IBRX | 26.28% | $3.73B | +43.05% | 0.00% |
| FR | 25.58% | $7.01B | +17.57% | 2.72% |
| COLD | 25.36% | $6.30B | -20.69% | 3.97% |
| ALDX | 25.36% | $294.18M | +102.46% | 0.00% |
| KALV | 25.29% | $440.88M | +17.08% | 0.00% |
| GNL | 25.27% | $1.69B | -16.46% | 16.20% |
| GILT | 25.10% | $310.17M | -13.38% | 0.00% |
| LBTYK | 24.99% | $4.62B | +35.25% | 0.00% |
| KFRC | 24.88% | $1.10B | -8.71% | 0.66% |
| W | 24.72% | $5.11B | -15.44% | 0.00% |
| VRE | 24.58% | $1.70B | +35.93% | 1.29% |
| PLYM | 24.45% | $842.88M | -11.32% | 5.12% |
| NTLA | 24.41% | $1.44B | -50.35% | 0.00% |
| PCT | 24.36% | $1.93B | +208.73% | 0.00% |
| OMER | 24.24% | $349.44M | +258.93% | 0.00% |
| CRSP | 24.08% | $4.01B | -30.49% | 0.00% |
| CSV | 23.87% | $590.66M | +75.49% | 1.16% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| SOHU | -30.18% | $406.50M | +43.52% | 0.00% |
| CPRI | -28.91% | $2.36B | -58.95% | 0.00% |
| RLX | -21.16% | $1.69B | -17.76% | 0.00% |
| PEN | -19.27% | $9.10B | +2.99% | 0.00% |
| BSX | -17.47% | $133.13B | +63.29% | 0.00% |
| PULM | -17.05% | $19.83M | +202.98% | 0.00% |
| UHS | -15.08% | $12.98B | +44.66% | 0.41% |
| WKC | -14.49% | $1.61B | +30.46% | 2.33% |
| NHTC | -13.45% | $61.83M | +0.19% | 14.81% |
| AMCR | -13.07% | $14.29B | +7.03% | 4.94% |
| PFG | -12.47% | $19.25B | +16.58% | 3.30% |
| TLYS | -12.47% | $110.96M | -56.14% | 0.00% |
| DVA | -12.20% | $12.87B | +60.92% | 0.00% |
| BRC | -11.96% | $3.31B | +29.76% | 1.35% |
| NGNE | -11.92% | $223.88M | +32.95% | 0.00% |
| HSIC | -11.82% | $9.33B | +8.59% | 0.00% |
| HRB | -11.75% | $7.59B | +20.02% | 2.42% |
| HCA | -11.46% | $84.88B | +34.82% | 0.77% |
| HIG | -11.19% | $33.87B | +51.09% | 1.60% |
| MSDL | -11.15% | $1.83B | +0.66% | 7.26% |
ETF's related to ACRS
News
Yahoo
Jefferies upgraded Aclaris Therapeutics (ACRS) to Buy from Hold with a price target of $7, up from $2. BSI-045B is the first anti-TSLP showing clinical proof of concept in atopic dermatitis, which is likely supported by a differentiated binding profile, the analyst tells investors in a research note. The firm says the data support further development in placebo-controlled study for additional validation in AD and beyond. If successful, BSI-045B could be the first anti-TSLP in the crowded AD spac
Yahoo
BTIG upgraded Aclaris Therapeutics (ACRS) to Buy from Neutral with an $8 price target In a “transformative transaction,” Aclaris has acquired full ex-China rights to an anti-TSLP humanized mAb and anti-TSLP/IL4R bispecific mAb from Chinabased Biosion, the analyst tells investors in a research note. The firm says BSI-045B’s potency is likely best-in-class with 71-times greater potency versus tezepelumab and up to nine-times higher potency versus other anti-TSLP therapies in development. Based on
Yahoo
On Monday, Aclaris Therapeutics, Inc. (NASDAQ:ACRS) entered into an exclusive license agreement with Biosion Inc for worldwide rights (excluding Greater China) to BSI-045B and BSI-502, a preclinical-stage, novel bispecific antibody directed against both TSLP and IL4R. In a completed Phase 2a, single-arm, proof-of-concept trial in the United States in 22 patients with moderate to severe atopic dermatitis, BSI-045B was observed to have a pharmacodynamic, safety, and efficacy profile. BSI-045B is a
Yahoo
Aclaris also announced the appointment of two key executives.
Yahoo
Aclaris stock surges on inking an exclusive license agreement with Biosion for global rights to two of the latter's pipeline candidates, BSI-045B and BSI-502.
Yahoo
Biosion, Inc. (Biosion), a global R&D stage biotechnology company, today announced that it has entered into an exclusive license agreement with Aclaris Therapeutics (NASDAQ: ACRS) for worldwide rights (excluding Greater China) to BSI-045B, a potential First-in-class, clinical-stage, novel anti-TSLP monoclonal antibody, and BSI-502, a potential best-in-class, pre-clinical stage, novel bispecific antibody that is directed against both TSLP and IL4R.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.